RACHEL ZENTNER: Open Payments
NPI 1669813549 · HASTINGS, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$420 in 27 payments from 10 companies in 2025. Trend: 2023 $768 · 2024 $614 · 2025 $420
Food & beverage: $420
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $174 |
| Janssen Pharmaceuticals, Inc | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Gilead Sciences, Inc. | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
| Biogen, Inc. | 1 | $16 |
Products named: VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR, CAPLYTA, ARISTADA, Jornay PM, Epclusa, COBENFY.
Industry payments across NE — which companies pay providers there.
